Objectives: We describe a population of patients with multiple drug intolerances to anti-hypertensive medications (MDI-HTN) and investigated the efficacy of a novel treatment algorithm.
Primary Hyperaldosteronism (PHA) is the commonest curable cause of hypertension, affecting 5-15% of patients with the disease. In some patients with PHA, benign tumours formed in the adrenal gland(s) secrete aldosterone. In a microarray comparison of aldosteronomas with their paired normal adrenals where 19,594 genes were screened, a cAMP coupled biogenic amine-like receptor; GPR61 was amongst the most significantly up-regulated, 8-fold in tumours. Since GPR61 activation in vitro stimulates cAMP production, the major intracellular stimulus to aldosterone production, we hypothesise that GPR61 is a regulator of aldosterone that could be a novel therapeutic target. Adrenals post adrenalectomy from patients with PH, were collected. GPR61 expression was quantified by qPCR in 32 pairs of normal adrenals with their paired aldosteronomas. GPR61 tissue distribution was also measured in both human and mice. Protein was assessed by its distribution between adrenal zones via immunohistochemistry (IHC) and confocal microscopy. Functional evidence of GPR61 regulation of aldosterone secretion was sought using its surrogate low-affinity 5-HT-like ligand, 5-(nonyloxy)-tryptamine (5-N-O-T) in primary adrenal cell cultures. GPR61 knockout mice were monitored over normal and low salt diets and aldosterone measured at each time point. qPCR replicated the microarray result, showing a 5.87-fold higher expression (where ddCT expression difference was À2.56) in adenomas versus the normal adrenal, but with 4100-fold variation between patients. IHC of GPR61 showed the majority of staining to be in zona glomerulosa (ZG), the site of aldosterone synthesis. 5-N-O-T at 10 mM, (equilibrium dissociation constant K D ) for cloned GPR61, down regulates aldosterone secretion of primary adrenal cells. In the presence of angiotensin II, the physiological regulator of aldosterone, the down regulation of aldosterone was amplified (n ¼ 5; Po0.004). GPR61 knockout showed increased aldosterone production (n ¼ 10, P ¼ 0.05), most evident on a low salt diet. Structurally, GPR61 may be playing a role in the regulation of aldosterone secretion from ZG, and in the development of aldosterone-secreting tumours.
3A.02. Purinergic signalling and hypertension: a translational study Peripheral chemoreceptors located strategically at the bifurcation of the common carotid artery sense levels of gases in blood prior to delivery into the brain. These carotid body (CB) chemoreceptors provide a defensive reflex of hyperventilation and hypertension in response to systemic hypoxia. Both animal and human data show an increase in the sensitivity of the peripheral chemoreflex in conditions of hypertension. We recently found a major role for CB chemoreceptors in the development and maintenance of hypertension in a rat model of hypertension. Thus, in hypertension the CB develop aberrant tonic drive (''tone'') contributing to excessive sympathetic activity and hypertension. Hypothesis: Based on both the role of adenosine triphosphate (ATP) as a transmitter substance within the CB and an upregulation of purinergic P2X3 receptors on visceral afferents in disease states, we hypothesised that CB hyper-reflexia and/or aberrant tonic drive were mediated by P2X3 receptors. In spontaneously hypertensive rats and using single cell qPCR, we found that P2X3 receptor expression in chemosensitive primary afferent (petrosal) neurones was increased fourfold relative to levels in normotensive rats (Po0.01). P2X3 receptor antagonism using a highly potent/selective antagonist (AF-219, 8 mg/kg) normalised CB afferent reflex sensitivity and abolished CB tone. Next, we assessed whether P2X3 receptors may be a novel target to lower arterial pressure. AF-219 (8 mg/kg/h i.v.) produced a dose-dependent lowering of arterial pressure in hypertensive rats (diastolic: À30 ± 2 mmHg, Po0.01) and reduced sympathetic activity (44%; Po0.05), but was without effect in normotensive rats. To translate these findings, we found abundant P2X3 receptor expression in hypertensive human cadaveric CB tissue. Also, we are screening hypertensive participants for CB aberrant tone using low dose dopamine, an agent that suppresses CB excitability. In some hypertensive participants dopamine reduced chemoreflex sensitivity and resting minute ventilation, indicative of aberrant CB tone. We conclude that a clinical trial exploring the benefits of P2X3 receptor blockade as a novel anti-hypertensive strategy is justified.
3A.03. Blood-pressure associated variants in NPR3 affect human vascular smooth muscle cells proliferation and calcium response to angiotensin II Introduction: A recent genome-wide association study identified a locus within natriuretic peptide receptor C (NPR3) to be significantly associated with blood pressure (BP).
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Objective: To functionally characterise the effect of BP-associated SNPs (single nucleotide polymorphisms) at the NPR3 locus in the context of BP regulatory pathways. Methods: Primary human umbilical smooth muscle (HUASMCs) and endothelial (HUVECs) cells of different NPR3 genotypes were investigated. Genotype-specific mRNA and protein expression were assessed by qRT-PCR and western blotting. Open chromatin regions were assayed using formaldehyde-assisted isolation of regulatory elements (FAIRE). Cell proliferation and migration were detected by cell counting and scratch assays. Angiotensin II (AngII)-induced Ca 2 þ flux was detected using an intracellular fluorescent probe (calcium 6).
Results: The NPR3 risk allele (major allele) in HUASMCs was associated with lower endogenous mRNA (Po0.001) and protein levels. This was consistent with the intronic SNP rs1173747-minor allele being associated with an open chromatin state (Po0.05). Furthermore, major-allele expression led to increased cell proliferation (Po0.05) and Ca 2 þ response to AngII stimulation (Po0.05). No differences in migration rates were detected. No such genotypedependent characteristics were observed in HUVECs. Conclusions: This study has identified potential mechanisms for BP-associated SNPs within NPR3 to influence BP predominantly via the vascular smooth muscle.
1. Ehret, et al., Nature, 2011; 478(7367) : 103-9.
3A.04. Characterisation of a novel duplication mutation in KCNJ5 from a patient with an aldosterone producing adenoma Accounting for 5-10% of hypertension, Primary Aldosteronism (PA) is a condition in which one or both adrenal glands autonomously produce aldosterone, either through bilateral hyperplasia or unilateral aldosterone-producing adenomas (APAs). Recent exome sequencing has revealed that approximately 40% of APAs harbour somatic mutations in the gene KCNJ5, a G-protein regulated inwardlyrectifying potassium channel. In this study, exome sequencing of 87 surgically removed adenomas revealed a novel 12-bp mutation (A139-F142dup). This mutation encodes a duplication of a conserved AFLF motif upstream of the selectivity filter. Clinically, the 54-year-old male patient harbouring the mutant adenoma had severe PA (aldosterone 490 pmol/L, renin 2mU/L, ratio 296). This novel KCNJ5 mutant, when expressed in Xenopus oocytes, exhibited a G-protein-sensitive Na þ current, a shift in K þ /Na þ selectivity and a loss of inward rectification, while retaining Ba 2 þ sensitivity. Expression in the human adrenal carcinoma cell-line H295R led to a 2.3-fold increase in basal aldosterone production, which was not potentiated by addition of angiotensin II, the classical stimulator of aldosterone production. Despite trafficking to the plasma membrane, this novel mutant had reduced tetramer stability and plasma membrane expression. Sanger sequencing of this large cohort of patients supports the major role of somatic KCNJ5 mutations in APAs. Although resulting in similar functional effects to previous mutants, this novel mutation likely acts through an alternative mechanism due to its lack of angiotensin II sensitivity and decreased stability. The discovery of this novel mutation illustrates how the same clinical phenotype can be generated by different mechanisms, even within the same gene.
3A.05. Unilateral carotid body resection as an anti-hypertensive strategy: a proof of principle study in resistant hypertensive patients Background: Carotid bodies (CBs) are important in initiation and maintenance of hypertension in the spontaneously hypertensive rat. Our pre-clinical studies revealed high tonic CB activity in hypertension. Reversible CB inactivation reduces sympathetic vasomotor tone in hypertensive humans. We report the first prospective study to assess the effect of unilateral CB resection on blood pressure (BP) in resistant hypertensive patients (rHTN). Methods: 15 participants with rHTN prescribed on average 6 anti-hypertensive medications underwent unilateral CB resection: 8 women, mean age 53 ± 7 yr, mean BMI 31.1 ± 4.3 kg/m 2 . The CB was verified histologically in resected tissue post hoc in all but one patient. Participants were defined as responders where Z10 mmHg fall in mean oSBP was seen at 1, 3 and 6 month post-resection. Data are presented as mean change in BP (±SEM) and analysed using nonparametric ANOVA (Dunn's Multiple Comparison Test). Results: Screening office systolic (oSBP) and diastolic blood pressures (oDBP) were 180±6 and 106 ± 4 mmHg, respectively (mean ± SEM). 8/15 participants demonstrated a fall in oSBP Z10 mmHg persisting to 6 months.
Responders (n ¼ 8): At 1 month post-surgery, the mean oSBP and oDBP had fallen by 37 ± 6 mmHg and 20 ± 5 mmHg (Po0.01) respectively. The significant reduction persisted to 3 months (DoSBP À30±5 mmHg, n ¼ 8, Po0.05; DoDBP À14±3 mmHg, n ¼ 8, P40.05). By 6 months (DoSBP À23 ± 4 mmHg, n ¼ 8; DoDBP À12 ± 3 mmHg, n ¼ 8), 12 (DoSBP À18±11 mmHg, DoDBP À11±6 mmHg, n ¼ 8) and 24 months (DoSBP À23 ± 15 mmHg, DoDBP À12 ± 6 mmHg, n ¼ 2) the reduction was no longer statistically significant (P40.05). Non-responders (n ¼ 7): There was no statistically significant change in BP in the non-responder group (P40.05). Medication changes post-resection is a possible confounder. There was no difference in screening BP in this group compared to the responder group. Conclusion: Unilateral CB resection produced a 410 mmHg oSBP reduction in 53% of rHTN patients at 1 month, maintained out to 6 months. CB modulation remains a potential strategy to control blood pressure in some HTN patients. Future studies aim to understand why some patients failed to respond. It has been shown that a high salt intake is associated with an increased risk of obesity through sugarsweetened soft drink consumption. Increasing evidence also suggests a direct link. Our study aimed to determine whether there was an independent association between salt intake and obesity. We analysed the data from the rolling cross-sectional study-the UK National Diet and Nutrition Survey2008/09-2011/12. We included 458 children (52% boys, 10 ± 4 (SD)yrs) and 785 adults (47% male, 49 ± 17 yrs) who had complete 24 h urine collections. Salt intake was higher in overweight or obese individuals (see Table 1 ). Logistic regression analysis showed that a 1g/d increase in salt intake was associated with an increase in the risk of obesity by 27% (OR ¼ 1.27, 95% CI: 1.11-1.44, P ¼ 0.0003) and 28% (OR ¼ 1.28, 95% CI: 1.17-1.38, Po0.0001) in children and adults respectively, after adjusting for age, gender, ethnic group, household income, physical activity and total energy intake and, in adults with additional adjustment for education, smoking and alcohol consumption. Separate models where energy intake was replaced with total fluid consumption showed consistent association. Our study suggested that high salt intake is a potential risk factor of obesity independent of total energy or fluid intake. Further studies are needed to investigate the mechanisms. Background: Antihypertensive drugs are widely prescribed to lower blood pressure (BP), however there is significant inter-individual variation in treatment response, which may be due to genetic variation. By identifying genetic variants associated with a differential treatment response, it is hoped that pharmacogenetics may aid in the selection of optimal treatments. So far, only three genetic loci have been validated from pharmacogenetic genomewide association studies (GWAS), only for BP response to diuretics. It has been hypothesised that the loci associated with BP would also modify the effects of response to antihypertensives, however no significant pharmacogenetic associations have been found. Methods: We have derived novel methods to take advantage of data from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), where hypertensive patients were randomized to either a betablocker (BB) or a calcium-channel-blocker (CCB). A pharmacogenetic GWAS has been performed using genetic data for 3,804 Europeans from UK/Ireland and 2,468 from Scandinavia, followed by a combined meta-analysis. Subjects were restricted to those on monotherapy treatment, comparing BB vs CCB patients within a linear regression drug-gene interaction analysis for three BP-related phenotypes: systolic BP (SBP), diastolic BP (DBP) and heart rate (HR). The response was defined as the mean phenotype measure over all longitudinal visits whilst on monotherapy, and adjusted for several covariates, including baseline BP, to eliminate any confounding effects. Any subjects taking BB (or CCB) drugs at baseline were excluded, resulting in a total sample size of up to 1,659 UK and 961 Scandinavian subjects. Results: We have identified one novel genetic locus on chromosome 11, reaching genome-wide significance for HR response. Furthermore we performed an updated look-up for 79 SNPs published for BP and identified two variants with significant pharmacogenetic association after Bonferroni correction: another for HR response on chromosome 11, and one for SBP response on chromosome 4, each of which has potential relevance and functional support. This data is now contributing to a large scale GWAS meta-analysis for antihypertensive response, which we are leading within an international pharmacogenetics consortium, adapted to combine data from clinical trials and observational studies.
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5A.01 A novel 'dilute and shoot' liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine Alexander J Lawson, Kate E Shipman, Stephen George, Indranil Dasgupta Heart of England NHS Foundation Trust, Birmingham, West Midlands, UK Background: Arterial hypertension is one of the most preventable causes of premature morbidity and mortality with resistant hypertension reported to be present in 5 to 30% of the total hypertensive population. Despite the poor prognosis, as many as 53% of those with resistant hypertension are reported to be non-adherent to their prescribed medication. An objective test of adherence which is easy to administer, quick, inexpensive, and reliable, is therefore needed to identify patients with true resistance to antihypertensive drugs to optimise their treatment. Methods: We have developed a novel LC-MS/MS method for the detection of 23 commonly prescribed antihypertensive medications in urine. The validated method was subsequently applied to the analysis of urine from a cohort of 49 individuals who were taking at least one antihypertensive agent in the screening profile to determine their adherence. Results: The screening method was found to be reproducible, sensitive & specific with the limit of detection ranging between 0.1 to 1.0 mg/L. Sample preparation is rapid (30 sec) and simple, with a total analysis time of 11 min. The assay successfully identified the majority of drugs our cohort had admitted to taking (88%) with drugs not detected in urine potentially indicating non-adherence to prescribed medication. Conclusions: The performance of this simple, robust LC-MS/MS procedure is suitable for screening urine for the presence of commonly prescribed antihypertensive medications. The assay, which can easily be implemented in other laboratories, has the potential to significantly improve investigation and management of resistant hypertension. All patients felt that treating hypertension was either 'very' or 'quite' important. The mean MMAS8 compliance score for those answering 'very' was 0.8 (high adherence); the mean for those answering 'quite' was 2 (medium adherence). Interestingly, the group that thought hypertension control 'very important' and the group that thought it 'quite' important had the same rates of recognition of heart attacks and strokes as complications of hypertension. 17/27 patients said they had experienced symptoms as a result of their high blood pressure, contrary to clinical expectations for hypertension of the severity seen in this patient group. The most commonly quoted symptoms were headache, dizziness, hot flushes, and mood disorders (low mood, frustration, irritability). Other answers included chest tightness, palpitations, backache, constipation, and reduced vision. Concerningly, many patients had not consulted their GPs regarding these symptoms because they believed they were explained by their blood pressure. One patient was treating her severe headaches with extra doses of her anti-hypertensive medications. Many patients expected they would feel better if their blood pressure was lower. The gaps and inaccuracies in patient understanding identified by this study will be addressed with a leaflet for practitioners to give to patients at annual hypertension reviews. We hope this will improve treatment compliance and will reduce the risk of delayed diagnoses due to patients inappropriately attributing their symptoms to their hypertension.
PA.04. Safe withdrawal of anti-hypertensive medication in older people with dementia: a review of the literature Background: There is uncertainty about the value of anti-hypertensive therapy for individuals with dementia. 1 Any study examining the impact of withdrawing anti-hypertensives in people with dementia needs to be based on the best available evidence. Aim: To review the literature on the withdrawal of antihypertensive drugs, in older people with dementia. Methods: We undertook a mapping review (or 'review of reviews'); a comprehensive search strategy was applied to identify published reviews that reported upon anti-hypertensive withdrawal regimes in people aged 65 or older. Results: 4/182 identified papers were eligible for inclusion; few involved people with dementia. The results suggest 20-40% of older people could successfully withdraw from anti-hypertensive therapy at up to one year. There was little evidence to guide withdrawal by individual drug class. Fortnightly reductions in medication were reported, and in most participants any return to hypertension was gradual. Serious adverse events were reported in 2.3% of participants at one year.
Discussion:
No evidence based withdrawal protocol was identified for use in an older adult population, in particular for those with dementia. Although there was evidence that 20-40% of people could safely withdraw antihypertensives. Any future withdrawal protocol should be underpinned by these findings but would need to be supplemented by national best practice guidance, such as NICE hypertension guidelines 2 or the British National Formulary, and would need to be rigorously tested for feasibility and safety. PA.05. Patient and provider experience using a digital health offering with sensor technologies to guide hypertension management in the community pharmacy Background: NHS calls for aligned measurement and monitoring of medicines optimisation using patientcentered approaches. A FDA-cleared/CE-marked medical device provides objective measures of medication taking and daily habits, which supports the NHS position. The device is composed of an ingestible sensor (IS) to track medication-taking patterns and a wearable patch that measures activities of daily living patterns (AoDL) of rest, activity, and exercise. This information is then transmitted to a mobile device where it can be viewed via a software application. Objective: To evaluate the feasibility and patient and provider experience of using a digital health offering to manage blood pressure (BP) in rural community pharmacies.
Methods:
The offering was piloted in 15 pharmacies on the Isle of Wight. Patients returned to community pharmacy after one and two weeks, and pharmacists provided targeted counselling as guided by the digital information. BP was taken at each visit and patients answered usability questions at the last visit. Both patients and pharmacists completed satisfaction surveys subsequently. Results: Of the 34 patients with uncontrolled hypertension at baseline, approximately 30% met BP goals (o140/90) after 2 weeks. Eighty-eight percent of patients found the overall usability of the devices to be good and fairly good, while 85% of the patients rated the usefulness of the app as good and fairly good. Of the 15 patients who returned satisfaction surveys by mail, 100% found the experience to be positive, 87% felt more involved with clinical care, and 87% also found the information helped to improve compliance. In the pharmacist survey, all of the pharmacists surveyed (n ¼ 11) found the offering helped create a collaborative experience with their patients; 91% noted that the longitudinal trends in actual medication use and AoDL aided them in making treatment recommendations.
Conclusions: A digital information service offering that provides direct confirmation of medicationtaking and objective measures of AoDL helped pharmacists to identify specific factors contributing to uncontrolled hypertension. The pharmacists in this study could then focus appropriate, targeted interventions for achieving treatment goals in their patients. Aim: Percutaneous sympathetic renal artery denervation is available for the treatment of patients with resistant hypertension. We further investigated the safety and efficacy of a multi-electrode renal denervation system (EnligHTNt) in patients with severe uncontrolled hypertension.
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Methods and results:
The EnligHTN-II study is a post-market clinical investigation in which patients were assigned to one of three groups; Group A, office systolic BP (OSBP) Z160 mmHg and estimated glomerular filtration rate (eGFR) Z45 mL/min per 1.73 m 2 , Group B, OSBP Z140-159 mmHg and eGFR Z45 mL/min per 1.73 m 2 and Group C, OSBP Z140 mmHg and eGFR Z15 mL/min per 1.73 m 2 . For all three groups subjects were required to be on at least 3 anti-hypertensive medications (including 1 diuretic), or to have documented drug intolerance such that they are unable to take 3 anti-hypertensive drugs. 129 patients from Group A (average age 62±9.5 yrs taking on average 4.22 ± 2.21 anti-hypertensive medications) were included. Bilateral renal nerve ablation was performed using a percutaneous femoral approach. Baseline average OSBP was 181.9±16.2 mmHg, average office diastolic BP (ODBP) was 97.6 ± 16 mmHg, average daytime ambulatory SBP (ASBP) was 163.3 ± 17.5 mmHg, and average daytime ambulatory DBP (ADBP) was 91.6 ± 13.8 mmHg. At present, 103 6-month and 64 12-month follow-up visits are completed. The average reduction in OSBP/ODBP was 18.2/ 8.5 mmHg (SD 21.5/14.3) and 17.2/9.9 mmHg (20.9/ 13.3) at 6-and 12-month follow up respectively (Po0.0001 for all). The average reduction in daytime ASBP/ADBP was 7.9 (17.0) /4.8 (9.0) mmHg (Po0.0001 for both) and 7.6 (17.1) /4.0 (9.7) mmHg (P ¼ 0.0024/0.0049) at 6 and 12M follow up respectively. Significant changes in nocturnal and 24 h ambulatory BP was also observed. Neither eGFR nor serum creatinine changed significantly from baseline at either 6 nor 12-months follow up. Conclusions: In this real world, post-marketing study we demonstrate that multi-electrode renal denervation results in durable, highly significant and safe lowering of both office BP and ambulatory BP parameters in patients with severe uncontrolled hypertension up to 12 months following treatment. Aims: Intolerance of antihypertensive medications is a major cause of non-adherence to pharmacotherapy leading to poor blood pressure control in the hypertensive population. We investigated the role of a central iliac arteriovenous (AV) anastomosis in a woman with uncontrolled hypertension (HTN) due to multidrug intolerances (MDI). Methods and Results: A sixty-one year old Caucasian female with long-standing poorly-controlled HTN was referred with MDI. She was unable to take Amlodipine, Nifedipine, Lercanidipine, Lisinopril, Candesartan, Bendroflumethiazide, Indapamide, Spironolactone, Amiloride, Doxazosin, Bisoprolol due to unacceptable side effects. After multiple pharmacotherapeutic attempts over a one year period, she could only tolerate Nebivolol 2.5 mg daily, liquid Nifedipine solution 16 mg twice daily and one quarter Glyceryl trinitrate (GTN) 5 mg transdermal patch daily. Despite this BP control remained suboptimal and she was offered treatment with the ROX coupler device having declined renal denervation for personal reasons. At baseline, the office BP (OBP) was 165/92 mmHg and 24 h ambulatory BP (ABP) confirmed suboptimal control with an average daytime mean of 158/ 83 mmHg, nocturnal mean 126/65 mmHg. At 6 months after creation of a right-sided iliac AV anastomosis, OBP was reduced by 24/21 mmHg, and 24 h ABP daytime average by 14/12 mmHg. At this point her BP was sufficiently well controlled to allow discontinuation of the nebivolol and GTN patch with no further change in BP at 1 year follow up. Baseline and 6 month echocardiograms both showed mild LVH with no change in ventricular wall thickness or ejection fraction. There was no significant change in renal function post-AV anastomosis. Right heart catheterisation at 6 months showed normal pressure in the right heart and pulmonary system. Conclusion: This is the first report of a patient with MDI and uncontrolled HTN undergoing treatment with a central iliac AV anastomosis resulting in early and sustained OBP lowering to target levels and reduction in daytime mean ABP. This novel therapy appears to target mechanical properties of the circulation and may be of benefit in the management of patients with uncontrolled HTN including those with multiple medication intolerances.
PA.07. A central iliac arteriovenous anastomosis results in durable and
PA.08. Assessment of electronic patient records in two primary care centres for quality of prescribing and monitoring Janice Olaniyan, Maisoon Ghaleb, Soraya Dhillon, Paul Robinson University of Hertfordshire, Hatfield, UK Background: Research has indicated that the quality of prescribing in primary care could be improved, with 4.9% of all prescriptions being sub-optimally written, although serious errors were rare. Older patients and those on multiple medications were more at risk. 1 We have examined the Electronic Patient Records (EPR) of 2 general practices to establish baseline quality of prescribing. Methods: EPR were interrogated for prescriptions issued to a sample of patients Z65 years in a 12-month period. Prescriptions were classified as having either ''prescribing errors'' (e.g. unlicensed dose for age, dosing instructions ambiguous) or ''monitoring errors'' (e.g. renal monitoring recommended but not done) to identify areas of potential risk.
Results: 323 patients (mean age 75 years, range 65-98) receiving 2739 individual items were reviewed (average 8.5 per items patient, range 1-39) of which 216 (7.9%) of prescription items were sub-optimally written with 168 prescribing errors, 25 monitoring errors and 23 omissions. CV medication (BNF Chapter 2) accounted for 28% of prescriptions reviewed but only 22% of sub-optimal prescriptions (see Table 1 ). Conclusion: Errors in CV prescribing was no higher than expected, but there is room for improvement in the prescribing and monitoring of CV medication in primary care. Blood pressure (BP) is normally measured on the upper arm but occasionally this is not possible because of trauma or vascular access devices. In these circumstances, measurement of BP on the leg may be necessary. It may also be helpful when coarctation of the aorta is suspected and some would argue that it should form part of the initial assessment of patients with diagnosed hypertension, particularly the young. Despite this, there are currently no clinical guidelines for the measurement of leg BP. We reviewed the literature on how best to measure BP in the leg in an attempt to provide guidance for clinicians. A literature search was carried out on EMBASE, MEDLINE, CINAHL and Cochrane for English language articles pertaining to BP measurement in the leg and papers from 1967 to 2014 were sourced. Evidence suggests that BP should be measured in the ankle (rather than the thigh) if it is not possible to use the arm because it will be easier to place the cuff correctly. Also that systolic BP measured in the leg will be higher than if it is measured in the arm in most patients; diastolic readings will be similar in the arm and leg. Multiple, in clinic readings, are advisable to minimise further error from a white coat effect. If ankle measurements are used for the diagnosis and treatment of BP, the systolic target should be approximately 10 mmHg higher than the recommended clinic brachial systolic pressure of 140 mmHg However, there will still be a wide margin of error so it is better to look at BP trends in individuals' to guide decisions. Further studies are needed to investigate in detail the relationship of leg to arm BP measurements to define appropriate diagnostic and therapeutic targets in hypertension. Specific guidance on BP measurement in the legs and validation of appropriate BP automated monitors for legs is also indicated. Finally, appropriate definitions of white coat and masked hypertension based on leg measurements are needed so that patients may be appropriately managed if arm BP measurements are not possible.
PB.04. Individual patient data meta-analysis of self-monitoring of blood pressure (BP-SMART) Objective: Interarm differences (IAD) of 4 ¼ 10 mmHg in blood pressure (BP) are associated with greater incidence of cardiovascular disease. The effect of ethnicity on the prevalence of this difference has not been reported.
Methods: The Blood Pressure in Ethnic Groups
Study (BP-Eth), compared ethnicity and different methods of BP measurement in 770 people (300 White British, 229 South Asian, 241 AfricanCaribbean). Repeated BP measurements were obtained simultaneously in the right and left arm using two BP-Tru machines and comparisons made between the first reading, mean of 2nd/3rd and mean of 2nd-6th readings for patients with and without known hypertension. All patients had ambulatory monitoring (ABPM) with white coat effect (WCE) defined as 1st Clinic BP 4 ¼ 10 mmHg higher than ABPM. Results and Conclusion: No significant difference was seen in the prevalence of systolic IAD between ethnicities whichever combinations of BP measurement were used and regardless of hypertensive status. Prevalence of IAD fell as more measurements were used: first measurement (n ¼ 161, 22%), mean 2nd/3rd (113, 16%) and mean 2-6th (78, 11%) (first vs mean 2/3 and 2-6, Po0.001). People with a significant white coat effect were more likely to have Background: Recent literature has explored the possibility that high frequency and magnitude of blood pressure variation (BPV) may adversely affect cardiovascular (CV) outcome, and that quantifying this variation may be a useful prognostic indicator. However, the methodology of this literature is diverse and results have been mixed. Methods: A systematic review of primary studies investigating the relationship between 24 h or dayto-day BPV and CV outcome was undertaken. MED-LINE and EMBASE were searched for studies published in English and in full. Additional papers were found by hand-searching of the references of the resulting papers.
Results: 1184 hits yielded a final 21 papers investigating B32,000 participants predominantly from general or hypertensive populations of Europe and Asia.
Studies followed subjects for Z1 year and recorded fatal and non-fatal CV events. Blood pressure variability was commonly quantified using SD but novel indices such as average real variability (ARV) were also used. Eight studies were suitable for metaanalysis, resulting in the following effect sizes: standard deviation (SD) of daytime SBPV (five studies) HR ¼ 2.12 (P ¼ 0.03), I 2 ¼ 0%; SD of day-time DBPV (three studies) HR ¼ 0.89 (P ¼ 0.37), I
2 ¼ 1%; SD of night-time DBPV (four studies) HR ¼ 3.45 (P ¼ 0.0006), I
2 ¼ 87%; SD of 24-hour SBPV (three studies) HR ¼ 0.70 (P ¼ 0.48), I
2 ¼ 0%; ARV of 24-hour SBPV (two studies) HR ¼ 2.53 (P ¼ 0.01), I 2 ¼ 61%. Conclusions: Hazard ratios for SD of daytime systolic BPV, night-time systolic and diastolic BPV, and for novel index ARV showed a significant association with the incidence of CV events. We investigated the effect of 8 different inflatable cuffs on arterial pressure measurement in a healthy human upper arm. The following mechanical properties of each cuff were assessed: Young's modulus along length and across width, flexural rigidity and thickness. The cuffs were each placed with the artery indicator over the brachial artery and midway between the acromion and the olecranon. Interface pressures under the cuffs were obtained with Oxford Pressure Monitor sensors placed radially 90 0 apart at the mid-arm level with the cuff pressurised to 155 mmHg and then deflated to 0 mmHg. Each cuff was inflated three times at 90 second intervals. A numerical model using DICOM data was obtained from a Magnetic Resonance Image of the same arm and converted into 3D surfaces using ScanIP s software to enable Finite Element Analysis (FEA) using ABAQUS 6.10-1. The model arm was loaded with experimentally obtained interface pressures collected between 130 and 80 mmHg. FEA estimates of pressure around the brachial artery cuffs varied by up to 27 mmHg SBP and 17 mmHg DBP with different cuffs. Pressures within the cuffs varied up to 27 mmHg. Pressure transmission from the cuff to the arterial surface achieved a 95% transmission ratio with one rubber-bladdered cuff but varied between 76 and 88% for the others. Pressures around the artery circumference varied widely, even with a single cuff, due to non-uniform pressure distribution. Our simulation demonstrates a strong relationship between the elastic modulus of the cuff fabric and pressures at the arterial wall interface. SBP measured with two-layered cuffs of identical size and sleeve material was 14 mmHg higher with a rubber bladder than with a fabric bladder. One-piece cuffs showed SBP differences of up to 19 mmHg, the lower pressures being found with materials of higher elastic modulus. Although it has been assumed that a BP cuff applies a known value of pressure around the arm, we have demonstrated wide variations in pressures estimated within cuffs, at interfaces and at the arterial wall using cuffs of differing construction and materials. Blood pressure measurements may be critically affected by the cuff used, leading to potentially serious errors in assessment of cardiovascular risk.
PB.12. Can cuff compression of the brachial artery at the elbow improve oscillometric systolic blood pressure assessment by removing the effects of intervening sub-cuff tissue? Results: Pre-intervention oBP was 194 ± 4/ 110 ± 4 mmHg despite 4.9 ± 0.4 antihypertensive drugs. oBP reduced by 20±9/3±6 mmHg (P ¼ 0.052/ 0.57). The change in oSBP correlated with both baseline oSBP (R ¼ À0.56, P ¼ 0.03) and the number of ablations (R ¼ À0.62, P ¼ 0.02). 12/15 patients had left ventricular hypertrophy at baseline (iLVM: LVM indexed to body surface area 92.8 ± 5.9 g/m 2 ); mean iLVM did not change, but there was a strong trend in the 9 patients with a 410 mmHg reduction in oSBP following RDN (DiLVM À12.1±5.9 g/m 2 , P ¼ 0.07). The reduction in iLVM correlated with both baseline oSBP (R ¼ À0.52, P ¼ 0.04) and the change in oSBP post RDN (R ¼ 0.72, P ¼ 0.003). Basal MSNA burst incidence was 56±6 bursts/100 heart beats. Changes in MSNA were highly variable; À24 to þ 50 bursts/ 100 heart beats at 6 months. There were no correlations between baseline MSNA and baseline BP or CMR parameters, or between changes in MSNA and changes in BP or CMR parameters. In patients with lower MSNA frequency/kg body mass at baseline there was a trend for a greater reduction in LVM post RDN (R ¼ 0.52, P ¼ 0.08). Conclusions: This study supports the reduction in oSBP and LVM following RDN reported previously, but changes in MSNA were highly variable (some patients showed an increase in activity), and do not correlate with BP and CMR outcomes. The reduction in iLVM must reflect a lowering of BP independent of sympathetic drive, although high sympathetic activity may blunt the loss of LVM. Further assessment is required to understand the association between autonomic nervous system and cardiac remodelling post-RDN.
PC.02. Anti-inflammatory effects of anti-platelet drugs: implication for atherosclerosis
Kerry Layne, Paolo Di Giosia, Albert Ferro, Gabriella Passacquale King's College London, London, UK Background: Cardiovascular disease due to atherosclerosis is the leading cause of death worldwide. There is a strong association between pro-inflammatory CD14 þ þ CD16 þ monocyte levels and the presence of atherosclerosis. Our previous work showed that platelet activation is a main determinant in the acquisition of a CD16 þ phenotype by circulating monocytes. Using the influenza immunisation, a validated model of acute inflammation, we assessed whether anti-platelet therapy could modify the circulating monocyte profile under proinflammatory conditions. Methods: 75 healthy subjects were studied before and 48 hours after receiving the influenza immunisation, with or without concomitant treatment with anti-platelet agents, namely aspirin, clopidogrel, or ticagrelor. Blood samples were collected prior to the immunisation and again 48 hours later. Whole blood was immunostained for human anti-CD14 and anti-CD16. Flow cytometry was performed to assess monocyte populations. Serum was tested for highsensitivity C-reactive protein (hsCRP) and proinflammatory cytokine levels. Results: hsCRP rose from 1.422 ( ± 0.2919) mg/l at baseline to 1.945 ( ± 0.3289) mg/l post-immunisation, (p o0.0001), confirming the induction of inflammation. The monocyte phenotype in the untreated group showed significant changes postimmunisation, with the proportion of pro-inflammatory CD14 Introduction: Recent observational studies have shown varied association between antihypertensive drugs and digoxin with either cancer risk or prognosis. We studied the time to incident cancer in two large patient cohorts in relation to four antihypertensive drugs and digoxin. Methods: We studied a hospital admission based cohort of 525,046 patients admitted at least once to the Western Infirmary and Gartnavel hospitals between 1980 and March 2013. Patients were classified into 6 mutually exclusive groups based on monotherapy with either ACEI/ARB(AA), betablockers(BB), calcium antagonist(CCB), thiazides, digoxin and a control group without exposure to these drugs. All control subjects were included if they were not on the any of the above drugs and were aged 60-80 years at 1/4/2004. The inclusion criteria for the drug groups included new prescription of the drug after 1/4/2004, no previous prescription of any of the study drug, at least 90 days of prescription, discontinuation of the drug no later than 1 year before onset of cancer. Each of the 4 antihypertensive drug groups were mutually exclusive for any prescription for the other drugs while Figure 1 Abstracts the digoxin group included all subjects exposed to digoxin. Age and sex adjusted time to first cancer diagnosis and time to death from cancer diagnosis were performed. Results: 34,634 subjects fulfilled the inclusion criteria and of them 6,153 had a new diagnosis of cancer after 1/4/2004. During 8-year period followup 6,557 patients were diagnosed with cancer in the hospital cohort (2,313 gastrointestinal, 2,439 lung, 464 prostate, 321 breast cancers). The results of the multivariate adjusted Cox model for incident cancer are presented in Figure 1 . Conclusion: Exposure to digoxin or beta-blocker therapy appears to be protective against incident respiratory cancers while CCB increased risk. Thiazides are associated with increased GIT cancers. CCB use at diagnosis of breast cancer improved survival.
PC.04. Antihypertensive therapy and risk of admissions for mood disorders Introduction: Recent epidemiological studies show mood disorders and hypertension co-occur more frequently than expected by chance. Recent GWAS have shown calcium channel gene variants (CAC-NA1C and CACNB2) to be associated with bipolar disorders suggesting calcium channels may play a role in both conditions. We hypothesised that calcium channel blocker (CCB) treatment will be associated with a different or lower risk of mood disorders compared to other antihypertensives. Methods: Two cohorts were studied: the Glasgow Blood Pressure Clinic (GBPC) and a hospital cohort of admissions from two Glasgow hospitals. Prescription refill data from 2004-2013 was used to create monotherapy groups for ACE inhibitors/angiotensin-receptor blockers (AA), beta blockers (BB) and CCB with duration 490 days and a control of no antihypertensive exposure in the hospital cohort. In the GBPC and hospital cohort, patients were 418 and 40-80 years respectively. Admissions were classified as ICD-10 F30-39 or ICD-9 295-7.
Results: There were 1,927 eligible patients with 31 incident admissions for mood disorders in the GBPC over 10 years and 144,087 with 302 admissions over 5 years in the hospital cohort. In GBPC, BB showed a higher risk of admission (HR: 3.2, [95% CI: 1.2-8.6], P ¼ 0.017) compared to AA, while in the hospital cohort compared to controls BB (1.6[1.1-2.4], P ¼ 0.009) and CCB (1.8[1.1-3.0], P ¼ 0.014) showed higher risks (Figure 1) . Conclusion: Calcium antagonists may exert similar effects on mood symptoms compared to beta blockers. This association has not been previously recognised.
PC.05. Changes in blood pressure in patients with hypertension receiving usual care in randomised controlled trials: findings from a systematic review and meta-analysis Aims: To quantify the change in blood pressure, in control arms of BP intervention studies, included in a Cochrane review of allied health professional led interventions in the management of hypertension. Methods: We pooled the primary outcome of change in systolic and diastolic BP from baseline to final follow up reported in usual care control arms of included trials. Changes in BP were expressed as weighted mean differences pooled using generic inverse variance taking account of within patient correlation. Results: Data from 58 studies were included. Mean systolic BP fell by À3.9 mmHg (95% CI: À5.5 to À2.4) and diastolic BP fell by À2.7 mmHg (À3.4 to À1.9) during usual care. Heterogeneity between studies was marked (systolic I2 ¼ 97% and diastolic I2 ¼ 94%). Usual care either consisted of routine care only (45 trials) or care enhanced with educational support for health professionals or patients (13 trials). Type of usual care did not account for observed heterogeneity, however restricting analyses to 24 high quality studies indicated a trend towards greater BP reductions with enhanced usual care compared to routine care only: diastolic À4.6 mmHg (À6.5 to À2.7) for enhanced vs. À1.9 mmHg (À3.1 to À0.7; P ¼ 0.02) for routine care and systolic À6.9 mmHg (À11.5 to À2.2) for enhanced vs. À4.2 mmHg (À6.9 to À1.6; P ¼ 0.33) for routine care. Conclusions: Reductions in BP were seen in the control arms of BP intervention studies in this review, with greater reductions when usual care is enhanced. This trend should be considered when interpreting studies and designing future interventions.
PC.06. Albuminuria within the normal range is associated with increased vascular stiffness in Type 2 diabetes Gemma Currie, Joanne Flynn, Christian Delles University of Glasgow, Glasgow, UK Background: There is a continuous association between albuminuria and cardiovascular risk, even at levels below the traditional diagnostic threshold. We aimed to determine the relationship between lowlevel albuminuria and vascular stiffness in a cohort of normoalbuminuric type 2 diabetic patients. Methods: Forty type 2 diabetic patients (61 ± 7 years) with urinary albumin: creatinine ratio (UACR) of o30 mg/g (6.7±4.6 mg/g) attended for assessment. Blood pressure (138 ± 11/79 ± 9 mmHg) and body mass index (30.9 ± 4.6 kg/m 2 ) were recorded. Carotid-femoral pulse wave velocity (PWV; SphygmoCor) was assessed. Blood samples were taken for cholesterol (4.3 ± 1.1 mmol/L), glycated haemoglobin (HbA1c; 64±11 mmol/mol) and renal function (eGFR 92±16 mL/min/1.73m 2 ). Results: PWV (9.29 ± 1.43) was in the range expected for this age group. We found no correlation between PWV and factors traditionally thought to drive cardiovascular risk including age (r ¼ À0.003, P ¼ 0.987); systolic blood pressure (r ¼ 0.297, P ¼ 0.074); cholesterol (r ¼ À0.168, P ¼ 0.720) and HbA1c (r ¼ 0.062, P ¼ 0.720). There was no association between UACR and SBP (r ¼ 0.038, P ¼ 0.819). In contrast, we found a relationship between PWV and UACR (r ¼ 0.472, P ¼ 0.003). UACR remained the strongest determinant of PWV after adjustment for SBP, BMI, eGFR and gender. Conclusion: In this relatively low risk normoalbuminuric group of type 2 diabetic patients; albuminuria is associated with vascular stiffness independent of traditional cardiovascular risk factors. Albuminuria should be considered a continuum rather than a categorical measure, and efforts taken to minimise albumin excretion may translate into additional risk reduction. Introduction: The baroreflex is important in buffering acute changes in BP, and its dysfunction has been implicated diseases such as essential hypertension. 1 By quantifying mSNA burst incidence, one can derive measures of baroreflex sensitivity (BRS) in healthy humans (normotensive, NTNs). However, in hypertensive patients (HTNs) this 'standard method' of quantifying BRS fails, due to the high burst incidence typical in this disease state. We aimed to quantify the BRS using other measures of mSNA. Methods: We have written and implemented MA-TLAB (R2012b, Natick) scripts to efficiently analyse microneurography data from a cohort of agematched n ¼ 9 NTN and n ¼ 9 HTN men. DBP was binned, and the average mSNA burst area for that DBP was calculated. This average area was plotted as a function of DBP, the slope of which yields the BRS. Results: When computed with the standard method, the NTNs had a BRS that was À3.8±0.4%bursts/ mmHg and the HTN population had near-0 sensitivities that were poorly fit with a linear curve. When our new method for calculating BRS was used on a HTN participant with high burst incidence, the BRS was calculated as À1.04area/mmHg and was well fit with a linear curve (R 2 ¼ 0.81), compared to a slope of 2.29%bursts/mmHg calculated with the standard method -a relationship poorly fit with a linear regression (R 2 ¼ 0.33). Conclusion: This analytic method will prove useful in quantifying and comparing the baroreflex sensitivity in patients with high mSNA burst incidence (such as those with hypertension or heart failure).
PC.07. A novel method for quantifying baroreflex sensitivity in hypertensive patients
Moreover it could provide mechanistic understand of the baroreflex; previous studies have suggested that activating the baroreflex triggers two central mechanisms.
2 By quantifying the BRS by this new method, we have provided further insight into how SNA is controlled in the human brain, and how this control differs across disease states. Background and purpose: Congenital ventricular septal defects are among the most frequently reported congenital heart defects. The aim of this study was to investigate the response of LASER irradiation on induced ventricular septal defects. Subjects and Methodology: Twenty male rabbits who underwent induction for ventricular septal defects by cardiac puncture technique with age ranged 6-10 months enrolled in that study for one and half months. They were assigned into two groups: Group (A): The experimental group consisted of 10 rabbits who received routine animal care associated with LASER irradiation. Group (B):
Guyenet (2006
The control group consisted of 10 rabbits who received routine animal care alone. The program continued for one and half months. Sizes of the septal defects were measured for both groups at the beginning of the study and after the end of one and half months.
Results: There was significant decrease of size of the diameter of the induced ventricular septal defect with study group (percentage of improvement 22.17%) when compared with control group. Conclusion: It was concluded that LASER therapy can be considered as a promising therapy for congenital heart defects in animals and to be examined on children after then. University of Glasgow, Glasgow, UK Introduction: Recent studies have shown that low diastolic blood pressure is associated with increased cardiovascular outcomes especially in those with pre-existing cardiovascular disease (DBP 'J' Curve). Whether this has practical implications in real life hypertension practice is unknown. Methods: We analysed the achieved blood pressure of 6,072 patients between years 2 and 5 following initial presentation to the Glasgow Blood Pressure Clinic. Patients were classified into nine groups based on the area under the curve (AUC) of at least 3 blood pressure (BP) readings during this period. Multivariable adjusted 30 years survival analysis was performed using Cox proportional hazards model. Results: The age of first visit was 53±13 years, BMI 27.6 ± 5.2, baseline BP 169 ± 29/100 ± 18 mmHg, 52% were females, 60% drank more than 6 units of alcohol/week, 44% were ever smokers, 26% had prevalent CVD and 26% had eGFRo60. Of 6,072 individuals, 418(7%) achieved AUC-BPr140/80; 365(12%) had isolated systolic hypertension(ISH) (4140/o80 mmHg) of whom 98 had severe ISH (SBP4160/ DBPo80). There were only 199(0.7%) subjects with AUC-DBPo70 mmHg. 30 year survival data was available for 5,451 individuals with 1,662 all-cause deaths and 65,430 person-years of followup. Figure 1 presents the adjusted hazard ratios for cardiovascular mortality showing significant excess risk associated with DBPo80 only in subjects with SBP4160. Conclusion: In treated hypertensive patients, the DBP 'J 'curve is not apparent with achieved BP 2-5 years from presentation. This may be explained partly by the low likelihood of achieving DBPo70 2-5 years after commencing treatment.
PE.02. Phenotyping ''pseudo-resistant'' hypertension following supervised dosing Omar Mukhtar, Ali Roomi, Stephen Jackson King's College London, London, UK Introduction: Resistant hypertension represents a significant risk to patients and a therapeutic challenge for clinicians. Supervised dosing (SD) may help to discriminate between ''genuine'' resistance and non-adherence. Methods: A retrospective study was conducted of patients labelled ''resistant hypertensives'', in whom SD had been carried out between June 2009 and March 2015. All BP data were based on the mean of three individual readings at any given time point, with the same arm utilised on all occasions. A mean BP was calculated for all clinic visits prior to (pre-) and post-SD. On the day of SD, the ''baseline'' BP was recorded within 30 minutes of arrival. ''Postdosing'' BP was defined as the lowest BP achieved throughout SD. The groups were then ''phenotyped'' on the basis of their pressures.
Results: Approximately one-third of patients demonstrated BP profiles consistent with resistant hypertension, i.e., no discernible change in BP during or after SD. The remaining patients displayed ''pseudo-resistance'', and could be ''phenotyped'' into three distinct groups. The first demonstrated a reduced 'baseline' SBP on the day of SD, relative to previous clinic values; a further reduction in mean SBP was observed during SD, along with an improvement in subsequent clinic BPs relative to those recorded prior to SD. The second group demonstrated a fall in SBP during SD along with an improvement in subsequent clinic readings relative to those observed before SD; however, in this instance, the 'baseline' SBP at SD was not lower than the mean at prior clinic visits. The final group demonstrated 'sustained pseudo-resistance' with a fall in mean SBP during SD, but no change/ an increase in SBP during subsequent clinics when compared to those before SD. Discussion: In keeping with the published literature, we confirm that SD can distinguish patients with resistant hypertension from those exhibiting ''pseudoresistance''.
1 Having ''phenotyped'' this latter group into three distinct cohorts on the basis of their BP profiles, we believe that important therapeutic insights may be gained into patient behaviours by means of psychological analysis of these three groups. Background: NICE guidelines advise ascertainment of adherence and exercise patterns for blood pressure (BP) management. Yet, practitioners often have no objective means to measure these parameters. Novel CE-marked devices have been developed to capture and share information about medication-taking and activities of daily living (ADL), through an ingestible sensor (IS), a wearable sensor, and a mobile application. Objective: To evaluate the clinical outcomes, medical decisions, and patient-reported outcomes associated with using this digital health offering in patients with uncontrolled hypertension in rural primary practices in the United Kingdom. Abstracts Methods: Patients prescribed Z2 anti-hypertensives co-ingested the IS with prescribed BP medications whilst simultaneously wearing the wearable sensor for 2 weeks. Clinic BP was measured on days 1 and 14. Adherence and ADL patterns, were measured via the IS and wearable sensor. Subjects returned to the clinic at week 4 to discuss the next steps in therapy based on the data. Results: 151 patients met the inclusion/exclusion criteria, and 95% completed the 2 week trial. Out of those who completed the study, BP control (o140/ 90; o140/85 in diabetics) was achieved in 37% of patients after 2 weeks. The mean change in systolic blood pressure (SBP) was À9±17 mm Hg, and the mean change in diastolic blood pressure (DBP) was À5 ± 9 mm Hg. The average number of steps-per-day was 6,137±3,378. Interventions were tailored based on the data: 132 patients received medicines use reviews, 97 received adherence counseling, 17 had medication changes, and 2 were referred to a hypertension specialist (some patients received 2 or 3 of these interventions). Most patients (85%) had a good experience and thought the platform was easy to understand and convenient to use as measured by a satisfaction survey. Conclusions: In patients with uncontrolled blood pressure in everyday practice, the inclusion of a digital health service may help practitioners to identify the specific medication and lifestyle factors contributing to persistent hypertension, and to provide evidence-based advice and interventions for improved management. Background: There is clear guidance from NICE on the management of hypertension through pregnancy. The difficulty arises when patients with pre-existing hypertension become pregnant and need to optimize medications in order to avoid any potential teratogenicity. The management and outcome of these patients and their babies is largely unknown. We present here a real world analysis of these individuals. Methods: All consecutive patients with known hypertension between 2010-2013 were included in the analysis. Follow-up was curtailed at Dec 2013 to ensure at least 12 months which captures both gestational period and the puerperium. The primary outcome measure was adherence to NICE guidance on management of hypertension in Pregnancy. Secondary outcomes were efficacy of anti-hypertensives and occurrence of intrauterine growth restriction (IUGR). Results: In total 54 patients were identified with complete clinical follow-up (100%). 57% 435years of age and 63% had a BMI 430 with 17% smokers and 65% multi-para. 89% were Caucasian, 5% Asian, 4% Afro-Caribbean and 2% South-East Asian. Pre-pregnancy: 76% were on either ACEI, ARB, Alpha or Calcium channel blocker. Only 42% were on either Methyldopa or Labetolol. At booking 13% were on antihypertensives contraindicated in pregnancy namely ACEI, ARB or diuretics. In total 512 BP measurements were made throughout gestation and resulted in 37% having medication changes not according to NICE guideline thresholds and 28% having no increase in medication despite BP consistently measured above threshold. All of the patients received fetal growth USS and 16% has either IUGR or low birthweight (o2.5Kg). The overall compliance to NICE guidance was 89% with a preference for Methydopa over Labetolol due to perceived IUGR with the latter. The occurrence of IUGR on both agents was however similar. Conclusion: The majority of patients were managed according to NICE guidance. However, there was a sizeable group that did not have medication optimised through pregnancy and there was a high rate of IUGR and low birthweight babies in this cohort. This study supports the notion for dedicated Pregnancy Hypertension Clinics and for better education and awareness of patients with preexisting hypertension who fall pregnant. Methods: We reviewed electronic health records of all patients referred to our centre over 2 years. Medication schedules were compared to each other by summating % of maximal licensed dose to give a total whole medicine equivalent (WME). The treatment algorithm was based on the use of sequentially initiated monotherapies or combinations of maximally tolerated doses of: fractional tablet doses; liquid formulations; trans-dermal preparations; offlabel tablet medications. Results: Of 782 referred patients, 79 had MDI-HTN (intolerance to at least 3 classes of anti-hypertensive medications) of whom 55 had complete records. Baseline office BP was 178±24/94±15 mmHg; home BP was 164±18/92±12 mmHg. At baseline, patients were intolerant to 7.6 ± 3.6 anti-hypertension medications; they were receiving 1.4 ± 1.1 medications delivering 0.8±0.8 WME. After 6 months on the novel MDI-HTN treatment algorithm, clinic BP was reduced by 13 ± 5/5 ± 2 mmHg (Po0.05 for both); home BP was reduced by 11±4/8±3 mmHg (Po0.01,Po0.05) whilst patients were now receiving 2.0 ± 1.2 medications delivering 0.8 ± 0.9 WME. At 12 months (n ¼ 41), clinic BP was reduced from baseline by 17±5/9±3 mmHg (Po0.01, Po0.05); home BP was reduced by 11 ± 5/12 ± 3 mmHg (Po0.01 for both) whilst patients were receiving 1.9 ± 1.1 medications delivering 0.7±0.7 WME. Conclusions: 10% of referred patients had MDI-HTN, resulting in insufficient pharmacotherapy and severe uncontrolled hypertension. Application of a stratified medicines approach allowed patients to tolerate increased numbers of medications and achieved significant and durable BP lowering.
PE.06. Vascular properties in women who had pre-eclampsia: the cardiovascular consequences of pre-eclampsia study (COPS) Background: Women with a history of pre-eclampsia (PE) are at higher risk of cardiovascular disease later in life. We evaluated the cardiovascular health of women who had PE in comparison with women who had normotensive pregnancies. Methods: Women were recruited from the previous Proteomics in Pre-eclampsia (PIP) Study, the Generation Scotland Scottish Family Health Study and the Glasgow Blood Pressure Clinic (pregnancies 1-5, 10-30 and 1-30 years ago, respectively).We assessed heart rate-adjusted augmentation index (AIx; SphygmoCor), carotid-femoral pulse wave velocity (PWV; SphygmoCor), carotid intima-media thickness (CIMT; ultrasound) and brachial flow-mediated dilatation (FMD; ultrasound). Results: A total of 166 women (86 cases, 80 controls) attended for vascular studies. Women with a history of PE had higher systolic blood pressure (SBP) (130±14 vs 122 ± 10 mmHg; Po0.001) and diastolic blood pressure (DBP) (82±9 vs 78±7 mmHg; P ¼ 0.001) compared with controls. They also had a higher BMI (29.4 ± 6.1 vs 26.6 ± 4.5 kg/m 2 ; P ¼ 0.002). We found impaired endothelial function (FMD 5.9±3.3 vs 7.0±3.3 %, P ¼ 0.017) and greater PWV (7.8±1.6 vs 7.1 ± 1.1 m/s, P ¼ 0.002) and heart rate-adjusted AIx (25.7±11.0 vs 22.5±9.6 %, P ¼ 0.023) in cases compared with controls. There was no difference in CIMT (P ¼ 0.110). After adjustment for age, BMI and SBP the difference in endothelial function remained statistically significant (P ¼ 0.014). Conclusions: Women who had PE have higher blood pressure and BMI compared to women at similar age who had normotensive pregnancies. A history of PE is also associated with impaired endothelial function which could explain the higher cardiovascular risk in this group. PE.07. Usual blood pressure and risk of new onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies Simon Anderson, Connor Emdin, Mark Woodward, Kazem Rahimi
The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, UK Background: Reliable quantification of the association between blood pressure (BP) and risk of new onset type 2 diabetes is lacking. Methods: A prospective cohort of 4.1 million adults, free of diabetes and cardiovascular disease, was identified using validated linked electronic health records. Cox models examined the relationship between usual BP and time to incident diabetes, using serial BP measurements to adjust for regression dilution. Analyses were complemented by a meta-analysis of prospective studies that reported relative risks of new onset diabetes per unit of systolic blood pressure (SBP). Random effects meta-analysis, adjusted for regression dilution, was used to pool relative risks. Results: Among a cohort of 4.1 million adults, 20 mm Hg higher SBP was associated with a 58% Background: We have previously shown that smoking and heavy alcohol intake is associated with high blood pressure (BP) and stiff arteries in untreated hypertensive patients. However, whether there is an interaction between smoking and heavy alcohol intake with initial antihypertensive response in previously untreated hypertensive patients is not well studied. Design & Methods: We studied 305 untreated hypertensive subjects (mean age 51 ± 1, mean ± SEM) classified according to smoking status into smokers, non-smoker and ex-smoker. Alcohol intake was classified as non-drinkers; moderate drinkers (males; o21 units/wk; females 414 units/ wk) and heavy drinkers (males; Z21; females Z14 units/wk). Systolic and diastolic BP was measured before and after1 month of monotherapy with commonly used antihypertensive agents at standard doses in previously untreated hypertensive patients. Data were analyzed using with JMP version 7.1 (SAS) for Windows. Results were expressed as mean ± SEM, with Po0.05 considered significant.
Results: There was a significant linear relationship between smoking status, alcohol intake and fall in systolic (Po0.05) and diastolic BP (Po0.05), with current smoking and heavy drinking associated with the lowest BP reduction after one month of antihypertensive monotherapy. In a stepwise regression analysis, baseline systolic BP, smoking status, alcohol intake and waist circumference predicted the fall in systolic BP with a significant interaction between smoking and heavy drinking. Similar results were observed for fall in diastolic BP. Discussion: Smoking and alcohol are in independent predictors of the initial antihypertensive response in treatment-naïve hypertensive patients. Furthermore, smoking and heavy drinking have an additive effect in reducing the BP response to antihypertensive agents. Considering control rats of hypertension to be o50% after initial antihypertensive treatment, the importance of smoking cessation and reduction in alcohol are paramount. Background: A potentially important mechanistic role for inflammation in the pathogenesis of hypertension is recognised. However, whether inflammation precedes development of hypertension or is a result of hypertension is not understood. We studied longitudinal associations between markers of inflammation and hypertension incidence over 20 years of follow-up in a bi-ethnic British population.
PE.09. Markers of inflammation predict incident hypertension in a population-based cohort
Methods: Population based study of non-hypertensive (i.e. no treatment and clinic BPo ¼ 140/90 mm Hg) South Asians and Europeans recruited in west London (1988-91) and aged 40-70 years. Inflammatory markers were glycoprotein acetyls(GlycA: 5 inflammatory markers produced in liver and adipose tissue-mostly alpha1-acid glycoprotein, an acute phase protein) and C-reactive protein(CRP)) Baseline serum CRP was measured using a high
